ResMed Inc. (ASX:RMD) disclosed that its board of directors was reduced from eleven to ten members effective November 18, 2026, following the retirement of director Ronald Taylor at the company's 2026 annual meeting of stockholders, while the company's Compensation and Leadership Development Committee also approved a redesigned performance-based restricted stock unit award structure for fiscal year 2027.

Key Points

  • Ronald Taylor did not seek re-election at the November 18, 2026 annual meeting, reducing the board from eleven to ten directors.
  • The Compensation and Leadership Development Committee approved a new form of Performance-Based Restricted Stock Unit Award Agreement on November 19, 2026, for named executive officers.
  • The new PSU design measures performance over three fiscal years against annual Adjusted EPS and Adjusted Revenue goals, replacing a design based on absolute and relative total stockholder return.
  • A relative TSR modifier ranging from 0.75 to 1.25 applies to earned PSUs, based on the company's TSR percentile rank relative to S&P 500 companies over a three-year TSR Period.
  • Stockholders at the annual meeting elected ten directors, ratified PricewaterhouseCoopers LLP as auditor for fiscal year ending June 30, 2027, and approved named executive officer compensation on an advisory basis.

Ronald Taylor Board Retirement and Director Election at 2026 Annual Meeting

At the annual meeting of stockholders held on November 18, 2026, Ronald Taylor did not seek re-election and his term expired at the conclusion of the meeting. Effective the same date, the size of the ResMed board was reduced from eleven to ten directors. Stockholders elected ten nominees to serve on the board until the company's 2027 annual meeting and until their successors are elected and qualified. Stockholders also ratified the selection of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2027, and approved named executive officer compensation on an advisory basis.

Fiscal Year 2027 Performance-Based Restricted Stock Unit Award Design

On November 19, 2026, the Compensation and Leadership Development Committee approved a new form of Performance-Based Restricted Stock Unit Award Agreement under the ResMed Inc. 2009 Incentive Award Plan, as amended and restated. Grants were approved for fiscal year 2027 to the company's named executive officers. Under the new design, the number of PSUs earned is determined by performance against Adjusted EPS and Adjusted Revenue goals set by the committee for each of three consecutive fiscal years beginning with fiscal year 2027. One-third of the target PSUs is allocated to each annual measurement period and split equally between the two metrics. Performance at threshold, target, and maximum results in payouts of 50%, 100%, and 200% of allocated target PSUs respectively, with linear interpolation between levels and no payout below threshold.

Relative TSR Modifier and Vesting Conditions for PSU Awards

Following the end of the performance period, payout percentages for each metric are averaged across the three annual measurement periods and weighted equally. The resulting percentage is then multiplied by a relative TSR modifier ranging from 0.75 to 1.25, based on the company's TSR percentile rank relative to S&P 500 companies over the TSR Period. The modifier is 0.75 at or below the 25th percentile, 0.95 at the 50th percentile, 1.00 at the 60th percentile, and 1.25 at or above the 75th percentile, with linear interpolation between points. In no event may more than 200% of target PSUs be earned. Earned PSUs vest upon committee certification of performance following the end of the performance period, subject to continued service through the certification date.